2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a has been researched along with Barrett Esophagus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allamaneni, SS; Cooper, MT; Dougherty, TJ; Henderson, BW; Nava, HR; Tan, W; Wilding, G | 1 |
| Bellnier, DA; Dougherty, TJ; Greco, WR; Loewen, GM; Nava, H; Oseroff, AR; Pandey, RK; Tsuchida, T | 1 |
1 trial(s) available for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a and Barrett Esophagus
| Article | Year |
|---|---|
Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Barrett Esophagus; Chlorophyll; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Photochemotherapy; Photosensitizing Agents; Precancerous Conditions; Treatment Outcome | 2011 |
1 other study(ies) available for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a and Barrett Esophagus
| Article | Year |
|---|---|
Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Blood Proteins; Carcinoma, Basal Cell; Chlorophyll; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Humans; Lung Neoplasms; Middle Aged; Neoplasms; Photochemotherapy; Photosensitizing Agents; Skin; Skin Neoplasms | 2003 |